Comprehensive cervical cancer screening includes HPV 31

You screen for HPV 16 and 18 – so why not 31?

There are 12 clinically relevant high-risk genotypes: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59.¹ HPV genotypes vary in prevalence, but also in their risk to cause cervical lesions.^1-3

Some genotypes are relatively prevalent but do not pose much risk for cancer while some are less common but pose a substantial risk for precancer and cancer.¹

• HPV 16, 52, 51, 39, 59, and 31 are the most common genotypes in a general screening population in the US (in order of prevalence)¹
• HPV 16, 31, 52, 51, 18 and 58 are the genotypes most frequently associated with high-grade cervical lesions in the US (in order of prevalence)¹
• HPV 31 poses a higher risk for cervical precancer as compared to HPV 18²

If you screen for HPV 16 and 18, then you should screen for HPV 31 because it poses a higher risk for developing cervical precancer than HPV 18.^1,2,4

But not all HPV tests can identify HPV 31.⁵ The BD Onclarity™ HPV Assay is the only FDA-approved HPV test with extended genotyping capabilities and that provides an individual result for HPV 31^5,6

Extended genotyping provides you with the precise results you need to assess the risk for cervical cancer^2,3,7 and is aligned with both ACS and ASCCP HPV risk-based guidelines.^4,8

Download the brochure to learn more.

References: 1. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in United States of America. Summary Report 22 October 2021. Accessed July 1, 2022. 2. Stoler MH et al. Gynecologic Oncology. 2019;153(1):26–33. 3. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1–13. 4. Perkins RB et al. J Low Genit Tract Dis. 2020;24(2):102–31. 5. Salazar KL et al. J Am Soc Cytopathol. 2019;8(5):284–92. 6.BD Onclarity™ HPV Assay Package Insert [8089894]. 7. Bonde J et al. J Low Genit Tract Dis. 2021;25(1):27–37. 8. ACS’s Updated Cervical Cancer Screening Guidelines Explained. Last update: 18 Sept 2020. Accessed: 19 May 2022. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2020/cervical-cancer-screening-hpv-test-guideline.